204 related articles for article (PubMed ID: 29022233)
1. Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors.
Shah C; Gong Y; Szady A; Sun Q; Pepine CJ; Langaee T; Lucas AR; Moreb JS
Cardiovasc Toxicol; 2018 Apr; 18(2):184-191. PubMed ID: 29022233
[TBL] [Abstract][Full Text] [Related]
2. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM
Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity due to targeted anticancer agents: a growing challenge.
Shah CP; Moreb JS
Ther Adv Cardiovasc Dis; 2019; 13():1753944719843435. PubMed ID: 30995890
[TBL] [Abstract][Full Text] [Related]
4. Maximizing anthracycline tolerability in hematologic malignancies: Treat to each heart's content.
Oliveira GH; Al-Kindi SG; Caimi PF; Lazarus HM
Blood Rev; 2016 May; 30(3):169-78. PubMed ID: 26578029
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy and Cardiotoxicity in Hematologic Malignancies.
Stellitano A; Fedele R; Barilla S; Iaria A; Rao CM; Martino M
Curr Cancer Drug Targets; 2017; 17(4):311-324. PubMed ID: 27903214
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline-induced cardiotoxicity in adult hematologic malignancies.
Johnson SA
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S22-7. PubMed ID: 16781286
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity of molecular-targeted drug therapy.
Le DL; Cao H; Yang LX
Anticancer Res; 2014 Jul; 34(7):3243-9. PubMed ID: 24982327
[TBL] [Abstract][Full Text] [Related]
8. Drug-related cardiotoxicity for the treatment of haematological malignancies in elderly.
Malato A; Saccullo G; Fazio G; Vergara B; Raso S; Guarneri GP; Russo A; Abbadessa V; Siragusa S
Curr Pharm Des; 2010; 16(26):2872-9. PubMed ID: 20632949
[TBL] [Abstract][Full Text] [Related]
9. Assessment and Management of Cardiotoxicity in Hematologic Malignancies.
Bojan A; Torok-Vistai T; Parvu A
Dis Markers; 2021; 2021():6616265. PubMed ID: 33613788
[TBL] [Abstract][Full Text] [Related]
10. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
Pai VB; Nahata MC
Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
[TBL] [Abstract][Full Text] [Related]
12. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
[TBL] [Abstract][Full Text] [Related]
13. Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future.
Yang B; Papoian T
J Appl Toxicol; 2018 Jun; 38(6):790-800. PubMed ID: 29369373
[TBL] [Abstract][Full Text] [Related]
14. Cardiac complications in cancer treatment - A review.
Li X; Liu M; Sun R; Zeng Y; Chen S; Zhang P
Hellenic J Cardiol; 2017; 58(3):190-193. PubMed ID: 28011332
[TBL] [Abstract][Full Text] [Related]
15. Doppler echocardiography during the follow-up of hematological patients undergoing chemotherapy.
Marra F; Galderisi M; Camera A; Rinaldi CR; Innelli P; Rotoli B; de Divitiis O
Int J Cardiol; 2007 Jan; 114(3):403-4. PubMed ID: 16626820
[TBL] [Abstract][Full Text] [Related]
16. Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities.
Guha A; Armanious M; Fradley MG
Trends Cardiovasc Med; 2019 Jan; 29(1):29-39. PubMed ID: 29910109
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
Rossi M; Carioli G; Bonifazi M; Zambelli A; Franchi M; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Eur J Cancer; 2016 Jan; 52():41-9. PubMed ID: 26630533
[TBL] [Abstract][Full Text] [Related]
18. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of anthracycline cardiotoxicity in children and adults.
Grenier MA; Lipshultz SE
Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
